Discovery and characterization of a cytochrome b5 variant in humans with impaired hydroxylamine reduction capacity

Pharmacogenetics and Genomics

Volumn 17, Issue 8, 2007, Pages 597-603

  Kurian, Joseph R ^b   Longlais, Brett J ^a   Trepanier, Lauren A ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

2 amino 1 methyl 6 phenylimidazo 4, 5 b pyridine; 4 aminobiphenyl; Cytochrome b5 reductase; Sulfamethoxazole

Indexed keywords

4 BIPHENYLAMINE; COMPLEMENTARY DNA; CYTOCHROME B5 REDUCTASE; HYDROXYLAMINE; MESSENGER RNA; PROTEASOME; PYRIDINE DERIVATIVE; SULFAMETHOXAZOLE;

ANIMAL CELL; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DEGRADATION KINETICS; FEMALE; GENE EXPRESSION; GENE SEQUENCE; GENETIC VARIABILITY; HELA CELL; HETEROZYGOTE; HUMAN; HUMAN CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETICULOCYTE LYSATE; RNA TRANSLATION; WILD TYPE;

AMINO ACID SUBSTITUTION; CYTOCHROMES B5; DNA MUTATIONAL ANALYSIS; ESCHERICHIA COLI; GENE EXPRESSION REGULATION; HELA CELLS; HUMANS; HYDROXYLAMINE; KINETICS; MUTANT PROTEINS; OXIDATION-REDUCTION; PROTEIN BIOSYNTHESIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA, MESSENGER;

ESCHERICHIA; MAMMALIA; ORYCTOLAGUS CUNICULUS;

EID: 34447298906     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328011aaff     Document Type: Article

References (24)

1. 5 catalyze the microsomal reduction of xenobiotic hydroxylamines and amidoximes in humans. J Pharmacol Exp Ther 2004; 311:1171-1178.
2. Cribb AE, Lee BL, Trepanier LA, Spielberg SP. Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adv Drug Reactions Toxicol Rev 1996; 15:9-50.
3. Crofts FG, Sutter TR, Strickland PT. Metabolism of 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine by human cytochrome P4501A1, P4501A2 and P4501B1. Carcinogenesis 1998; 19:1969-1973.
4. Culp SJ, Roberts DW, Talaska G, Lang NP, Fu PP, Lay JO Jr, et al. Immunochemical, 32P-postlabeling, and GC/MS detection of 4-aminobiphenyl-DNA adducts in human peripheral lung in relation to metabolic activation pathways involving pulmonary N-oxidation, conjugation, and peroxidation. Mutat Res 1997; 378:97-112.
5. Bewley M, Marohnic C, Barber M. The structure and biochemistry of NADH-dependent cytochrome b5 reductase are now consistent. Biochemistry 2001; 40:13574-13582.
6. Giordano S, Kaftory A, Steggles A. A splicing mutation in the cytochrome b5 gene from a patient with congenital methemoglobinemia and pseudohermaphrodism. Hum Genet 1994; 93:568-570.
7. Hegesh E, Hegesh J, Kaftory A. Congenital methemoglobinemia with a deficiency of cytochrome b5. New Engl J Med 1986; 314:757-761.
8. Vergeres G, Waskell L. Cytochrome b5, its functions, structure and membrane topology. Biochimie 1995; 77:604-620.
9. Wu Y, Wang Y, Qian C, Lu J, Li E, Wang W, et al. Solution structure of cytochrome b(5) mutant (E44/48/56A/D60A) and its interaction with cytochrome c. Eur J Biochem 2001; 268:1620-1630.
10. Gan J, Wu J, Wang Z, Wang Y, Huang Z, Xia Z. Structures of V45E and V45Y mutants and structure comparison of a variety of cytochrome b5 mutants. Acta Crystallogr D Biol Crystallogr 2002; 58 (Pt 8):1298-1306.
11. Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W. Current protocols in immunology. In Coico R, editor. Current Protocals in Immunology. New York: John Wiley & Sons; 1994. pp. 7.1.1-7.1.2.
12. Trepanier L, Yoder A, Bajad S, Beckwith M, Bellehumeur J, Graziano F. Plasma ascorbate deficiency is associated with impaired reduction of sulfamethoxazole-nitroso in HIV infection. J Acquir Immune Defic Syndr 2004; 36:1041-1050.
13. Trepanier L, Bajad S, Kurian J. Evaluation of the cytochrome b5/cytochrome b5 reductase pathway. In: Hodgson E, editor. Current protocols in toxicology. Hoboken, New Jersey: John Wiley & Sons; 2005. pp. 4.16. 11-14.16.17.
14. Trepanier L, Miller J. NADH-dependent reduction of sulphamethoxazole hydroxylamine in dog and human liver microsomes. Xenobiotica 2000; 30:1111-1121.
15. Kurian J, Chin N, Longlais B, Trepanier L. Reductive detoxification of aromatic hydroxylamine carcinogens by human NADH cytochrome b5 reductase and cytochrome b5. Drug Metab Rev 2005; 37 (S2):265.
16. Wang L, Sullivan W, Toft D, Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation. Pharmacogenetics 2003; 13:555-564.
17. Percy MJ, Crowley LJ, Boudreaux J, Barber MJ. Expression of a novel P275L variant of NADH: cytochrome b5 reductase gives functional insight into the conserved motif important for pyridine nucleotide binding. Arch Biochem Biophys 2006; 447:59-67.
18. Jenkins M, Prchal J. A high-frequency polymorphism of NADH-cytochrome b5 reductase in African-Americans. Hum Genet 1997; 99:248-250.
19. Percy MJ, Gillespie MJ, Savage G, Hughes AE, McMullin MF, Lappin TR. Familial idiopathic methemoglobinemia revisited: original cases reveal 2 novel mutations in NADH-cytochrome b5 reductase. Blood 2002; 100:3447-3449.
20. Jenkins MM, Prchal JT. A novel mutation found in the 3′ domain of NADH-cytochrome B5 reductase in an African-American family with type I congenital methemoglobinemia. Blood 1996; 87:2993-2999.
21. Barham HM, Inglis R, Chinje EC, Stratford IJ. Development and validation of a spectrophotometric assay for measuring the activity of NADH: cytochrome b5 reductase in human tumour cells. Br J Cancer 1996; 74:1188-1193.
22. Fitzsimmons S, Workman P, Grever M, Paull K, Camalier R, Lewis A. reductase enzyme expression across the NCI tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 1996; 88:259-269.
23. Giordano S, Steggles A. The human liver and reticulocyte cytochrome b5 mRNA's are products from a single gene. Biochim Biophys Res Commun 1991; 178:38-44.
24. Borgese N, D'Arrigo A, DeSilvestris M, Pietrini G. NADH cytochrome b5 reductase and cytochrome b5 isoforms as a model for the study of post-translational targeting to the endoplasmic reticulum. FEBS Letters 1993; 325:70-75.